INTRODUCTION
Lentiviruses such as human immunodeficiency virus (HIV) and feline immunodeficiency virus (FIV) are able to integrate their genomes into the chromosomes of nondividing target cells. Because of this property, which is not shared by oncoretroviruses like the murine and avian leukemia viruses, lentiviruses are special candidates for transduction of nondividing human cells in gene therapy applications (Buchschacher and Wong-Staal, 2000; Trono, 2000) . To date, five lentiviruses have been used to generate gene transfer systems: HIV-1 (Miyoshi et al., 1999; Naldini et al., 1996b) , HIV-2 (Arya et al., 1998; Poeschla et al., 1998a) , FIV (Poeschla et al., 1998b) , simian immunodeficiency virus (SIV) (Schnell et al., 2000) , and equine infectious anemia virus (EIAV) (Mitrophanous et al., 1999; Olsen, 1998) . Gene transfer systems derived from the sheep virus Visna (Sigurdsson et al., 1957; Staskus et al., 1991) , the cow virus bovine immunodeficiency virus (BIV) (Garvey et al., 1990 ; Van der Maaten et al., 1972) , and the goat virus caprine encephalitis virus (CAEV) (Crawford et al., 1980) have not been reported.
Gene transfer systems based on HIV-1 are by far the most developed systems, with documented in vivo transduction of rat brain Naldini et al., 1996a,b) , retina (Miyoshi et al., 1997 (Miyoshi et al., , 1998 ) muscle, and liver , and mouse trachea (Johnson et al., 2000) . Mouse pancreatic islets were transduced ex vivo and transplanted in vivo, with stable expression of the transgene (Gallichan et al., 1998) . In addition, HIV-1-derived vectors transduced human corneal tissue ex vivo (Wang et al., 2000) . Moreover, unstimulated human hematopoietic stem cells transduced in vitro have developed into mature T (Douglas et al., 2000) and B cells (Miyoshi et al., 1999) in in vivo models of lymphocyte maturation.
Although HIV-1 vectors are the most well studied, some authors suggested that HIV-based vectors pose safety risks for human clinical applications (Buchschacher and Wong-Staal, 2000; Trono, 2000) . The possibility has been raised that, if the HIV-1 vector recombines with endogenous human retroviruses (ERVs) present in the cells or with exogenous viruses present during transient infections, there is a chance of generating replication-competent HIV-1 or transferring the vector to other cells in the patient. Such a recombination event is less likely to occur for nonhuman, or even nonprimate vectors. In addition, even if the nonprimate lentivirus were to become replication-competent, it might not be as destructive as HIV-1 in humans, although the point has been debated (Trono, 2000) .
We chose to study the ability of Visna virus (Sigurdsson et al., 1957; Staskus et al., 1991) to mediate gene transfer to human cells. A successful lentiviral gene transfer system must allow for easy production of hightiter, replication-defective virus capable of transducing a large percentage of nondividing cells in such a way that the therapeutic gene is expressed at high per-cell levels for a long period of time (months to years). Toward this end, a panel of packaging constructs was generated and evaluated in a transient expression system for virus production, maturation, and vesicular stomatitis glycoprotein (VSV-G) pseudotyping. Similarly, a panel of vectors was generated and evaluated for RNA expression and encapsidation into virions. Some vector/packaging construct combinations produced levels of virus similar to those of an analogous HIV-1 gene transfer system. However, the Visna virus was impaired in reverse transcription and integration in the target cells, regardless of the cell type.
RESULTS

Two-plasmid gene transfer system
As a first step in generating Visna virus-based gene transfer systems, a panel of Visna mutants was generated ( Fig. 1 ) and tested for virus production, maturation, and infectivity. The virus was modified in three ways. First, the 5Ј LTR U3 region was replaced with the human cytomegalovirus (CMV) immediate-early promoter (see constructs VisCa and VisCb, Fig. 1 ). The junction between the 3Ј edge of the CMV promoter and the 5Ј edge of the adjoining Visna R region differed in the two constructs: in VisCa the DNAs were joined at the respective transcription start sites, while in VisCb the DNAs were joined at the respective TATA boxes. Second, approximately 800 bp were deleted from the interior of the env gene of VisCaBX in such a way as to retain expression of the rev gene. Third, a DNA cassette consisting of the mouse phosphoglycerate kinase (PGK) promoter and the enhanced green fluorescent protein (eGFP) cDNA was inserted into the ϳ800-bp gap in the env gene (see VisCaPG and VisCbPG, Fig. 1 ). Similarly, a cassette consisting of the CMV promoter and the eGFP cDNA was inserted into the same env deletion in the wild-type Visna plasmid, generating construct VXCG. These eGFP-containing constructs, when expressed in cells coexpressing a suitable viral envelope protein, may form virus particles capable of transducing fresh cells.
The constructs were then evaluated in a transient expression system for cytoplasmic gag mRNA levels, cell-associated Gag protein levels, virion-associated Gag protein levels, and virion reverse-transcriptase activity (Fig. 1) . The human kidney carcinoma cell line 293T was transfected with each construct and, after 2 days, the cytoplasmic RNA was assayed for Visna gag mRNA content ( Fig. 2A , first five lanes). VisCa and VisCaBX expressed higher steady-state levels of gag mRNA than did VXCG and wild-type Visna, indicating that the Visna LTR is less active than the CMV promoter in 293T cells. In addition, the virus shed from the transfected cells was assayed for reverse-transcriptase (RT) activity (Fig. 1,  Experiment 1 ). VisCa and VisCaBX produced more RT activity, and hence more viral particles, than did wild-type Visna, likely because of the elevation in gag mRNA levels. VisCb and VisCbPG produced only slightly more particles than did wild-type Visna. Strangely, the VXCG preparation contained no RT activity, even though this construct expressed wild-type levels of gag mRNA ( Fig.  2A) .
In the same experiment, virus particles were collected by centrifugation and evaluated by Western blot assay, using antiserum specific for Visna Gag protein (Fig. 2B , first seven lanes). In general, the relative amount of virion-associated Gag protein correlated well with the relative amount of RT activity (see Fig. 1 ). Construct VXCG contained no detectable virion-associated Gag protein, indicating that the construct must have been blocked in either Gag protein translation or virion assembly. In addition, all of the constructs' virus preparations contained primarily capsid protein instead of Gag polyprotein, indicating that none of the constructs was defective in virus maturation. In a separate experiment, transfected 293T cells were assayed for Visna Gag protein by Western blot. Wild-type Visna expressed low levels of Gag protein in the transfected cells, while VisCa and VisCb expressed high levels ( Fig. 1 ; data not shown).
To determine with more confidence the levels of virus produced by the constructs, RT assay was performed on shed virus in three more series of transfections (Fig. 1 , Experiments 2-4). The patterns of virus production observed originally (in Experiment 1) were confirmed: the CMV-driven constructs produced up to fourfold more virus than did wild-type Visna, although there was some variability from experiment to experiment. In addition, the constructs produced levels of virus comparable to those produced by a CMV-driven HIV-1 packaging construct (Douglas et al., 2000) (Fig. 1) .
Since VisCaPG and VisCbPG produced high levels of virus, the viruses shed from transfected 293T cells were pseudotyped with VSV-G (Burns et al., 1993; Yee et al., 1994) and tested for their ability to transfer the eGFP cDNA into new cells. The cell lines used were 293T; CEMSS, a human lymphoid cell line; and sheep choroid plexus (SCP) cells, which support wild-type Visna virus replication (Staskus et al., 1991) . Despite the fact that eGFP was expressed well in the transfected cells, eGFP was not detected to any significant degree in the infected cells (Fig. 3) . In contrast, a VSV-G-pseudotyped HIV-1 control virus preparation, containing the packaging construct depicted in Fig. 1 and a vector containing an internal PGK-eGFP cassette (Douglas et al., 2000) , transduced the cells readily. The experiment was repeated several times; the highest transduction efficiency observed was 3%, by VisCbPG (data not shown).
Three-plasmid gene transfer system
Since VisCaPG and VisCbPG were poorly infectious, the viral genes and eGFP cDNA were separated onto two plasmids. Four packaging constructs were generated, in which the Visna gag and pol genes were inserted be-tween the CMV promoter and the SV40 late polyadenylation signal (Fig. 1) . The 3Ј 325 bp of the Visna leader, including the major splice donor site (MSD), was retained in constructs VH2 and VH3, although construct VH3 was deleted in 89 of the 186 bp between the MSD and gag; such a deletion might impair encapsidation of the packaging construct mRNA, by analogy with other retroviruses (Berkowitz et al., 1996) . In contrast, constructs VH1 and VH4 retained minimal leader sequences, and were modified by insertion of a small, FIG. 4 . Visna vectors and their levels of full-length RNA expressed in transfected cell cytoplasm. Left, schematics of Visna vectors; indicated regions include the 5Ј portion of the gag gene, the 3Ј portion of the env gene, the putative Visna packaging signal (), the long-terminal repeats (LTR), the major splice donor site (SD), and the rev 3Ј splice acceptor site (SA). Indicated non-Visna regions include the human cytomegalovirus immediate-early promoter (CMV), the murine phosphoglycerate kinase promoter (PGK), the MND promoter (Robbins et al., 1997) , the enhanced green fluorescent protein cDNA (eGFP), a small chimeric intron from plasmid pCI (intron flanked by SD and SA), and a fragment containing the HIV-1 RRE. The positions of transcriptional initiation are indicated with arrows. Right, measurements of cytoplasmic, full-length vector RNA expression, as determined by Northern assay. In Experiment 1, the amounts of vector RNAs were not directly measured, but were estimated based on the intensity of the bands on the autoradiogram. ϩ/Ϫ, low-intensity or undetectable band; ϩ, band of intermediate intensity; ϩϩ, band of high intensity. In Experiment 2, the amounts of vector RNAs were measured by direct quantitation of the radioactivity on the rinsed Northern blot (see Fig. 5 ).
FIG. 1.
Visna packaging constructs and their levels of virus produced. Left, schematics of virion-producing Visna mutants and packaging constructs. Indicated regions include the gag, pol, env, tat, and rev genes, the long-terminal repeat (LTR) and rev-response element (RRE), the major splice donor site (MSD), and the tat splice acceptor site (SA). Indicated non-Visna regions include the human cytomegalovirus immediate-early promoter (CMV), the murine phosphoglycerate kinase promoter (PGK), the enhanced green fluorescent protein cDNA (eGFP), a small chimeric intron from plasmid pCI (in), a fragment containing the HIV-1 RRE, and an internal ribosome entry site from encephalomyocarditis virus (Jang et al., 1989) linked to the puromycin N-acetyltransferase cDNA (IRES-puro) (Vara et al., 1986) . Right, measurements of virus production. Direct measurements were performed for Northern analysis of gag mRNA expression (see Fig. 2a ) and reverse-transcriptase assay (four experiments), while Western analysis of Gag protein content (see Fig. 2b ) was estimated from the intensity of the stained bands. Ϫ, no band detected; ϩ/Ϫ, low-intensity band; ϩ, band of intermediate intensity; ϩϩ, band of high intensity. chimeric intron upstream of gag. Constructs VH1-VH3 contained all Visna coding regions downstream of pol, except for approximately 1.4 kb of envelope sequences. In contrast, packaging construct VH4 contained Visna sequences terminating 487 bp downstream of pol. Since VH4 does not contain the rev-response element (RRE) and the rev gene, the HIV-1 RRE was inserted downstream of pol and the HIV-1 rev protein was added in trans when VH4 was evaluated for expression. In addition, VH4 was modified by insertion of the puromycin N-acetyltransferase cDNA (Vara et al., 1986) coupled to an internal ribosome entry site (IRES) from the encephalomyocarditis virus (ECMV) (Jang et al., 1989) , for selecting cell lines stably producing the packaging construct.
The four packaging constructs were evaluated in the transient expression system for steady-state cytoplasmic gag mRNA levels, cell-associated Gag protein levels, virion-associated Gag protein levels, and virion reversetranscriptase activity as before (Fig. 1 ). VH2-VH4 expressed high levels of gag mRNA in the transfected 293T cells, comparable to that expressed by VisCa ( Fig. 2A) . The fact that construct VH4's gag mRNA level was not higher than those of the other packaging constructs suggests that the Visna rev/RRE system functions as efficiently as the HIV-1 rev/RRE system in 293T cells. VH2 produced large amounts of virus, as detected by RT assay and Gag Western blot ( Fig. 1 and Fig. 2B ), even more than that produced by the HIV-1 packaging construct. VH3 produced less virus than did VH2, while VH1 and VH4 produced a lot less virus than did VH2 ( Fig. 1 and Fig. 2B ). Very little VH1 Gag protein was detected in the transfected cells, indicating a block in Gag protein expression ( Fig. 1 ; data not shown). In contrast, VH4 produced high levels of Gag protein in the transfected cells, suggesting that this construct is blocked in virion assembly ( Fig. 1 ; data not shown).
A panel of Visna-based vectors was also created, all of which contained the eGFP cDNA inserted into a deletion of the viral coding region (Fig. 4) . Three different types of vectors were created: the "VV1" vectors retained short gag (86-bp) and env (324-bp) segments; the "VV2" vectors retained longer gag (578-bp) and env (1169-bp) segments, including the RRE (Tiley and Cullen, 1992) ; and the "VV3" vectors contained the longer gag segment, the short env segment, and a 515-bp HIV-1 env segment containing the HIV-1 RRE. Each of the vector types contained the PGK promoter linked to eGFP, either with or without a small chimeric intron between the two segments. In addition, a seventh vector (VV2-MG) was generated, using vector type "VV2" and containing the myeloid proliferative sarcoma virus (MPSV, or "MND") promoter (Robbins et al., 1997) linked to eGFP. Each of the seven vectors contained a chimeric 5Ј LTR in which CMV promoter sequences, up to the TATA box, were linked to the Visna LTR sequences following the TATA box.
The vectors were first analyzed for their steady-state expression levels in human cells. Each of the vectors was introduced into 293T cells along with packaging construct VH3 and, 2 days later, the cytoplasmic RNA was assayed for vector RNA content. First, vectors VV1-PG, VV1-PIG, and VV2-PG were analyzed, using a probe that detects both full-length RNAs (driven by the chimeric 5Ј LTR) and internal RNAs (driven by the PGK promoter). Although the amounts of the vector RNAs were not quantitated, visual inspection of the autoradiogram indicated that the three vectors expressed different amounts of the different RNAs (Fig. 4 and data not shown). VV1-PG expressed high levels of internal RNA and low levels of full-length RNA, while VV1-PIG expressed extremely high levels of internal RNA but no detectable full-length RNA. VV2-PG produced intermediate levels of full-length RNA and internal RNA, as well as high levels of spliced RNA [i.e., between the MSD and the rev splice acceptor (SA) site].
The experiment was repeated, using vectors VV2-PG, VV2-PIG, VV3-PG, and VV3-PIG and a probe that detects only LTR-driven, not internal, RNAs (Fig. 5) . As before, the VV2-PG vector was observed to express intermediate-tohigh levels of full-length RNA ("F") and 1-kb spliced RNA ("S"; Fig. 5 ). The VV3-PG vector, which lacks the Visna rev splice acceptor site, expressed only the full-length vector RNA but not the spliced RNA (Fig. 5) . The amount of full-length VV3-PG RNA was quantitated and found to be comparable to the amount of full-length VV2-PG RNA. This result indicates either that the Visna rev protein functions efficiently with the HIV-1 RRE, in contrast to a previous study (Tiley and Cullen, 1992) , or that the rev/ RRE system is not required for the cytoplasmic expression of the full-length vector RNAs. In contrast, the VV2-PIG and VV3-PIG vectors, containing a chimeric intron between the PGK promoter and eGFP, expressed low levels of full-length vector RNA (Fig. 5 and Fig. 4 ). However, both vectors expressed high levels of a 2 to 2.5-kb RNA species ("SЈ") generated by splicing between the MSD and the chimeric intron SA. This splicing event also predominated over splicing between the MSD and the rev SA, since the 1-kb spliced RNA was not detected. The 2 to 2.5-kb SЈ RNA occasionally underwent further splicing, presumably between cryptic splice donor sites in eGFP or Visna env and the rev SA, since other RNA species (Fig. 5, 1 .9 and 1.6 kb in first lane) were present for vector VV2-PIG but not for VV3-PIG, which lacks the rev SA.
To determine the ability of the Visna vectors to transduce human cells, virus collected from 293T cells tripletransfected with VH2, VSV-G, and either VV2-PG, VV3-PG, or VV2-MG was analyzed by RT assay and exposed to fresh 293T cells. Each vector expressed high levels of eGFP in the transfected cells (Fig. 6) . Three days later, the infected cells were analyzed for eGFP expression by flow cytometry. The VV2-PG virus produced 496 pg of RT activity and transduced 4% of the cells, the VV3-PG virus produced 779 pg of RT activity and transduced 1% of the cells, and the VV2-MG virus produced 630 pg of RT activity and transduced 5% of the cells. In contrast, an HIV-1 control virus consisting of the packaging construct depicted in Fig. 1 and a vector containing an internal MND-eGFP cassette produced 1289 pg of RT activity and transduced 100% of the cells. The transduced cells were kept in culture and analyzed 2 weeks postinfection: 7% of the VV2-MG-infected cells were eGFP ϩ . Thus, while the efficiency of Visna transduction was low, the expression of the transgene was stable. A VV2-PG virus preparation was also used to transduce SCP cells; however, eGFP was not detected in the SCP cells 3 days postinfection (data not shown).
The reason for low transduction efficiencies
The inability of the Visna virus preparations to transduce cells readily was investigated. First, virus preparations were analyzed for VSV-G content and encapsidated vector RNA content. To determine whether the Visna virus particles were pseudotyped with the VSV-G protein, 293T cells were cotransfected with VH3 and a plasmid encoding VSV-G, then virions were collected and analyzed for VSV-G content by immunoblot assay (Fig. 7) . To provide a relative estimate of the efficiency of VSV-G incorporation, virus shed from 293T cells cotransfected with VSV-G and the HIV-1 packaging construct depicted in Fig. 1 was normalized by RT assay and analyzed concurrently. The amount of VSV-G protein contained on the Visna particles was not less than the amount on the HIV-1 particles (Fig. 7) .
To determine how well the full-length vector RNAs were encapsidated by Visna virions, 293T cells were triple-transfected with vector VV2-MG, packaging construct VH2, and the VSV-G plasmid. RNA was prepared from the collected virions and analyzed for vector RNA content, using an eGFP-specific probe that detects both full-length and internal vector RNAs (Fig. 8) . To provide a relative estimate of the efficiency of Visna vector RNA encapsidation, a control system consisting of the HIV-1 packaging construct depicted in Fig. 1 and the HIV-1 MND-eGFP vector (see above) was analyzed side by side with the Visna system ( Fig. 8 and Table 1 ). Since the full-length HIV-1 vector RNA is similar in size to the full-length Visna vector RNA and the two RNAs are detected with the same probe, the Northern analysis reli- ably indicates the relative amounts of the two RNAs. Moreover, since the Visna and HIV-1 RT proteins possess similar specific activities in the RT assay (data not shown), the vector RNA content can be normalized by the amount of virus. The Visna virus preparation contained 38% more full-length vector RNA than did the HIV-1 virus preparation, but also contained 21% more virus particles; as a result, the amount of full-length vector RNA per particle was 14% higher for Visna than for HIV-1. Since the transfected cell cytoplasm contained 72% more fulllength HIV-1 vector RNA than Visna vector RNA, the full-length Visna vector RNA was encapsidated with 97% higher efficiency than that of the full-length HIV-1 vector RNA.
Since the Visna virus preparations were not deficient in VSV-G or vector RNA content, the low transduction efficiencies were reasoned to be the result of deficiencies occurring during the infection process. To determine whether Visna was impaired in reverse transcription in the infected cells, the Visna (VV2-MG) and HIV-1 virus preparations analyzed in Fig. 8 were treated with DNase I, normalized for full-length vector RNA content using the information from the Northern blot assay, and used to infect fresh 293T cells. Twenty hours later, a portion of the cells was lysed and serial dilutions of the lysates were analyzed for vector DNA content by polymerase chain reaction (PCR) analysis (Fig. 9, Table 1 ). The PCR primers were located in the R region and near the gag start codon, to amplify DNA synthesized only when the process of reverse transcription was nearly completed. When tested on dilutions of the HIV-1 and VV2-MG plas- a The amount of full-length vector RNA in the virus RNA and cytoplasmic polyAϩ RNA preparations was inferred from the amount of labeled probe, which hybridized to the RNA on the Northern blot (see Fig. 8 ).
b The amount of virus was inferred from the amount of reverse transcriptase detected in the virus preparation. c The relative amount of full-length vector RNA per virion was calculated by dividing the amount of full-length vector RNA detected in the virus RNA preparation by the amount of virus.
d The relative packaging efficiency was calculated by dividing the relative amount of full-length vector RNA per virion by the amount of full-length vector RNA detected in the polyAϩ cytoplasmic RNA preparation.
e The lowest dilution of the indicated DNA sources containing detectable vector DNA was determined by PCR amplification of the dilutions, using vector-specific primers.
f The relative amount of unintegrated vector DNA synthesized in the infected cells 20 h postinfection was inferred by inverting the lowest dilution of cell lysate containing detectable vector DNA and factoring in the efficiency of the PCR primers (i.e., multiplying by the lowest dilution of plasmid DNA).
g The relative amount of integrated vector DNA contained within the infected cells 2 weeks postinfection was inferred by inverting the lowest dilution of genomic DNA containing detectable vector DNA and factoring in the efficiency of the PCR primers (i.e., multiplying by the lowest dilution of plasmid DNA).
h The percentage of transduced cells was determined by flow cytometric analysis of eGFP expression 2 weeks postinfection. i The relative amount of integrated vector per transduced cell was calculated by dividing the amount of integrated vector DNA by the percentage of transduced cells.
FIG. 8. Encapsidation of a Visna vector. Cytoplasmic polyA
ϩ RNA was prepared from 293T cells triple-transfected 2 days earlier with Visna vector VV2-MG, packaging construct VH2, and VSV-G, or with similar HIV-1 gene transfer constructs. In addition, RNA was prepared from virus collected from the transfected cells. The RNA preparations were analyzed for vector RNA content by Northern blot assay, using a probe from the eGFP cDNA. The full-length vector RNA is the upper band (3 kb for the HIV-1 vector, 3.3 kb for the Visna vector). In addition, eGFP is contained on internal HIV-1 (1.1-kb) and Visna (2.3-kb) mRNAs, which are not encapsidated. mids, the Visna primers were threefold less efficient than the HIV-1 primers (Fig. 9D) . When tested on the HIV-1 virus-infected cells, the HIV-1 primers detected vector DNA in the PCR reaction containing 0.03 cell-equivalents but not in the reaction containing 0.01 cell-equivalents (Fig. 9B) , indicating that approximately 30 copies of vector DNA were synthesized per cell. Visna vector DNA was detected in the PCR reaction containing 3 cellequivalents but not in the reaction containing 1 cellequivalent (Fig. 9C) , indicating that approximately one copy of vector DNA was synthesized per cell (factoring in the threefold inefficiency of the Visna primers). Since the same amount of virion-associated vector RNA was added to the cells, the Visna virus was roughly 30-fold defective, relative to HIV-1, in reverse transcription in the 293T cells (Table 1) . PCR amplification of endogenous ␤-globin DNA confirmed that the HIV-1-and Visna-infected cell lysates contained similar cell equivalents per unit volume (Fig. 9C) .
The cells were kept in culture and analyzed for eGFP expression 2 weeks postinfection. Some 76% of the HIV-1-infected cells were eGFP ϩ , while only 0.74% of the Visna-infected cells were eGFP ϩ (data not shown). Since the 100-fold difference in eGFP expression was greater than the 30-fold difference in reverse-transcription efficiency, the possibility arose that the Visna virus was impaired in another step during infection, e.g., vector integration. To determine whether the Visna virus was impaired in vector integration, the Visna-and HIV-1-infected cells were analyzed for integrated vector content by PCR assay, using the same primers as before (Fig. 10, Table 1 ). HIV-1 vector DNA was detected in genomic DNA 1000-fold more diluted than was Visna vector DNA; factoring in the threefold inefficiency of the Visna primers, the data indicate that the cells contained approximately 300-fold less integrated Visna vector DNA than HIV-1 vector DNA. Thus, in addition to the 30-fold impairment in reverse transcription, Visna was 10-fold impaired in vector integration, relative to HIV-1 (Table 1) . Moreover, since the 300-fold excess of HIV-1 vector DNA was distributed among 100-fold more transduced (i.e., eGFP-expressing) cells, each transduced cell, on average, likely contained approximately threefold more copies of the HIV-1 vector than of the Visna vector. Indeed, the HIV-1-infected eGFP ϩ cells exhibited a three-to fourfold higher mean-channel fluorescence (i.e., average fluorescence per cell) than did the Visna-infected eGFP ϩ cells (data not shown). Moreover, the HIV-1-transduced cells were found to contain 5-10 copies of the vector per cell (S. Tamaki, submitted).
To determine whether the defects of the Visna virus were the result of its production in human cells, the VV2-MG Visna virus was produced in sheep choroid plexus (SCP) cells, which are permissive for Visna virus replication (Staskus et al., 1991) . Because of the low transfection efficiency of SCP cells, relatively little virus was shed from the cells: only 14 pg of RT activity for the Visna virus and 2 pg of RT activity for the HIV-1 virus. The viruses were exposed to fresh SCP and 293T cells, after which the cells were cultured for 2 days and analyzed for eGFP expression. The VV2-MG virus transduced 1% of the 293T cells and none of the SCP cells, while the HIV-1 virus transduced 4% of the 293T cells and 1% of the SCP cells (data not shown). Since the Visna virus produced in SCP cells transduced 293T and SCP cells inefficiently, compared to that of HIV-1 virus production, the inefficient reverse transcription and integration of the Visna virus produced in 293T cells must not be the result of production in 293T cells per se. 
DISCUSSION
In this study we examined in detail the ability of Visna virus to serve as a gene transfer system for the infection of human cells. We found that Visna-derived packaging constructs could produce virus in amounts that were the same as or more than those produced by a comparable HIV-1-derived packaging construct; as with the HIV-1 virus, the Visna virus underwent efficient maturation and was efficiently pseudotyped by VSV-G. We also found that Visna-derived vectors could be encapsidated within the virus particles with an efficiency that is equal or superior to that of a comparable HIV-1 vector. Thus, the Visna gene transfer system produced as much potentially infectious virus as did the HIV-1 system. However, the undiluted VSV-G-pseudotyped virus produced by the Visna constructs inefficiently transduced human cells because of a 30-fold defect in reverse transcription and a 10-fold defect in vector integration. The defect was not the result of the human cells per se, since the Visna virus also poorly transduced sheep choroid plexus (SCP) cells, which support wild-type Visna virus replication. The low transduction efficiencies were also noted when the Visna virus was produced in SCP cells, indicating that the defect was not the result of improper viral assembly in certain cell types, as noted for vif mutants of HIV-1 (Gabuzda et al., 1992) . Instead, it is likely that the poor infectivity of the Visna virus resulted from generalized inefficiencies in reverse transcription and integration in the infected cells, regardless of cell type. The reverse-transcription deficit was not the result of a defect in reverse transcriptase per se, since the enzyme exhibited comparable specific activity to the HIV-1 reverse transcriptase in an in vitro assay. Moreover, transfection of the SCP cells with the wild-type Visna construct, which was shown by sequence analysis to be identical to the published clone (Staskus et al., 1991) , yielded syncytium formation after 10 days of culture, indicating that the virus is indeed infectious (unpublished observations).
Other nonhuman lentiviruses were reported to transduce human cells with efficiencies approaching those of HIV-1 (Berkowitz et al., submitted; Mitrophanous et al., 1999; Olsen, 1998; Poeschla et al., 1998; Schnell et al., 2000) , so it is surprising that the Visna vectors were poorly infectious. It is possible that the observed defects in reverse transcription and integration result from peculiarities of the Visna vectors instead of the viral enzymes. It would be interesting to determine whether the defects are also observed for the other infectious molecular clone of Visna, kv72 (Andresson et al., 1993) . If the de- fects are intrinsic to Visna in general, the virus would require further modification to generate a successful gene transfer system.
MATERIALS AND METHODS
Plasmids
All restriction endonucleases were obtained from Roche Molecular Biochemicals (Indianapolis, IN) unless otherwise noted. Plasmid pCI was obtained from Promega (Madison, WI). Plasmid pCIGL contains the vesicular stomatitis virus glycoprotein (VSV-G) cDNA (Burns et al., 1993; Yee et al., 1994) in the pCI polylinker, downstream of the human cytomegalovirus (CMV) immediateearly promoter and chimeric intron and upstream of the simian virus 40 (SV40) late polyadenylation signal. Plasmid pCrev, containing the HIV-1 rev cDNA under control of the CMV promoter, was described previously (Malim et al., 1988) . Plasmid pVis, containing the wild-type Visna clone LV1-1KS1 (Staskus et al., 1991) , was modified by conventional subcloning techniques, to generate packaging constructs and vectors as follows. First, plasmids pVAS and pVSX, containing short polylinkers in place of much of the Visna coding region, were generated by digesting pVis with ApaI and SgrI or SpeI and XbaI and ligating the small fragment to polylinkers created by annealing oligonucleotides VAS5 (5Ј-CCTCGAGGCGGCCGCG-CATGCTAGCCGCGGCA-3Ј) and VAS3 (5Ј-CCGGTGC-CGCGGCTAGCATGCGCGGCCGCCTCGAGGGGCC-3Ј) or VSX5 (5Ј-CTAGTCTCGAGGCGGCCGCGCATGCTAGCCGC-GGT-3Ј) and VSX3 (5Ј-CTAGACCGCGGCTAGCATGCGCG-GCCGCCTCGAGA-3Ј).
The CMV immediate-early enhancer/promoter was used to replace the Visna promoter in the 5Ј LTR in plasmids pVAS and pVSX, with the junction either at the two TATA boxes or at the two transcription start sites. First, the upstream CMV region was subjected to PCR amplification with primers CB5 (5Ј-CGGGATCCCGTAGTTATTAATAGTA-ATCAATTACGG-3Ј) and either CV3A (5Ј-TCTGCTTTTC-CCACGGTTCACTAAACGAGCTCT-3Ј) or CV3B (5Ј-GCG-GCTTATATAGACCTCCCACCGTACACGCCT-3Ј), while the downstream Visna region was subjected to PCR amplification with primers Vnru3 (5Ј-CACAAGAGCAACACTGGTA-AGG-3Ј) and either CV5A (5Ј-TTAGTGAACCGTGGGAAAAG-CAGAGTGCTTTGG-3Ј) or CV5B (5Ј-CGGTGGGAGGTC-TATATAAGCCGCTTGCTAGCTGG-3Ј). Second, the CMVand Visna-amplified products were mixed and subjected to amplification using primers CB5 and VN3. The two final products were digested with BamHI and NruI and ligated to plasmids pVAS and VSX, previously digested with BamHI and NruI, generating plasmids pVASCa, pVASCb, pVSXCa, and pVSXCb. The BamHI-SpeI fragment, containing the chimeric LTR, of plasmids pVSXCa and pVSXCb was then used to replace the corresponding fragment of pVis, generating plasmids pVisCa and pVisCb.
Plasmids pVisCa and pVisCb were digested with Bsu36I (New England Biolabs, Beverly, MA) and XbaI to delete interior env sequences; the large fragment was then ligated to a fragment from plasmid pHPEGFP (Douglas et al., 2000) containing the mouse phosphoglycerate kinase (PGK) promoter (Adra et al., 1987) linked to the enhanced green fluorescent protein (eGFP) cDNA (Promega), generating plasmid pVisCaPG and pVisCbPG. In addition, the pVisCa fragment was recircularized to produce plasmid pVisCaBX. Plasmid pVis was similarly digested with Bsu36I and XbaI and ligated to the CMV promoter linked to eGFP, generating plasmid pVXCG. Plasmids pVASCb and pVSXCb were linearized by digestion of the SphI site in the polylinker and ligated to the PGK-eGFP fragment, generating plasmids pVV1-PG and pVV2-PG, or to a similar fragment also containing the pCI intron, generating plasmids pVV1-PIG and pVV2-PIG. Plasmids pVV2-PG and pVV2-PIG were then digested with NsiI and SgrAI to delete most of the env sequences and ligated to a 500-bp fragment containing the HIV-1 rev-response element (RRE). Plasmid pVV2-MG was generated by digesting pVSXCb at the XhoI site in the polylinker and ligating the linearized fragment to an NdeI/NotI-digested fragment from plasmid pHSMPSVegfp containing the MND promoter (Robbins et al., 1997) linked to the eGFP cDNA. Plasmid pHSMPSVegfp is a variant of plasmid pHSMPSVlacZ (S. Tamaki, submitted) in which the ␤-galactosidase cDNA was replaced with the eGFP cDNA. Plasmid pVH1 was generated by sequential insertion of two pVis segments into the pCI polylinker using standard techniques: a 6-kb NruI-HincII fragment containing the gag, pol, vif, and tat genes, as well as the first coding exon of the rev gene; and a 1.2-kb XbaI-BstEII segment containing the RRE and the second coding exon of the rev gene. Plasmid pVH2 was generated in a similar fashion, but the large fragment contained an additional 222 bp of leader sequences, including the major splice donor site, and was inserted in place of the pCI chimeric intron. pVH3 is identical to pVH2 but contains a 89-bp deletion between the NruI and NheI sites upstream of gag. Plasmid pVH4 was constructed by insertion of a 5.1-kb NruI-CelII fragment, containing the gag and pol genes, but not the vif or tat genes, into the pCI polylinker. In addition, plasmid pVH4 possesses a fragment of HIV-1 containing the RRE, as well as an internal ribosome entry site (IRES) from encephalomyocarditis virus (Jang et al., 1989) linked to the puromycin N-acetyltransferase cDNA (Vara et al., 1986) . supplemented with 10% FCS. 293T cells (4-10 ϫ 10 6 ) or SCP cells (1-2 ϫ 10 6 ) were seeded into 10-cm dishes overnight and transfected the next day with 20-30 g plasmid DNA by the calcium phosphate method (Clontech, Palo Alto, CA). Typically, 20 g of the vector, 10 g of the packaging construct, and 3 g of the envelope plasmid were used. In cases where the HIV-1 rev protein was required, 4 g of plasmid pCrev was added. After 24-72 h the cells or the virus-containing medium was collected and analyzed in a variety of ways (see below). To assess the efficiency of transfection, a portion of the transfected cells was removed from the plate by exposure to EDTA or trypsin and analyzed for eGFP expression by flow cytometry using a FACScan (Becton Dickinson Biosciences, San Jose, CA). To measure the amount of virus shed into the medium, the medium was cleared of cellular debris by low-speed centrifugation, then 10 l was lysed and analyzed for RT activity using a commercial kit (Roche Molecular Biochemicals).
Analysis of RNA levels
Cells were lysed and cytoplasmic RNA was prepared using a commercial kit (Qiagen, Valencia, CA); in some instances, polyA ϩ RNA was isolated by a commerical kit (Qiagen). Virus-containing medium was collected, subjected to mid-speed centrifugation to remove cellular debris, and then subjected to high-speed centrifugation (50,000 g 90 min at 4°C) to pellet the virus particles. The viral pellet was lysed and the viral RNA was prepared using a commercial kit (Qiagen). A fixed amount of polyA ϩ RNA (usually 200 ng) or viral RNA (usually onethird of the RNA prep, not quantitated) was subjected to 1% agarose gel electrophoresis and transferred to a nylon filter (Bio-Rad, Hercules, CA). The filter was exposed to 40 ϫ 10 6 cpm of a DNA fragment randomprimed with 32 P-dCTP using a commercial kit (Ambion, Austin, TX), then washed and analyzed for bound probe with a phoshporimager (Molecular Dynamics, Sunnyvale, CA). The DNA fragments included a Visna 1.1-kb pol fragment, a 0.4-kb Visna leader fragment, a 0.5-kb Visna env/U3 fragment, and a 0.8-kb eGFP fragment.
Analysis of protein levels
Cells were lysed on ice for 1 h in a buffer containing 1% NP-40, 150 mM NaCl, 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, and Pefabloc protease inhibitor (Roche Molecular Biochemicals). The lysate was subjected to centrifugation at 8000 g 20 min at 4°C to remove precipitated proteins and other debris. Alternatively, virus-containing medium was collected, subjected to brief centrifugation to remove cellular debris, and then subjected to high-speed centrifugation (50,000 g 90 min at 4°C) to collect the virus particles. The viral pellet was lysed directly in SDS-PAGE sample buffer (Novex, San Diego, CA). A fixed amount of cell or viral lysate was subjected to acrylamide gel electrophoresis and transferred to a nitrocellulose filter. The filter was exposed to goat serum specific for Visna Gag protein (a gift of J. Clements), then to horseradish peroxidase (HRP)-conjugated rabbit anti-goat Ig antibody (Zymed, South San Francisco, CA), then to the HRP substrate OPD (Sigma, St. Louis, MO). Prestained molecular weight standards (Bio-Rad) were used to determine the approximate molecular weight of the labeled Visna Gag bands. For the VSV-G Western blot, the filter was exposed to mouse anti-VSV-G monoclonal antibody (Sigma) and then to the HRP-conjugated goat anti-mouse Ig antibody (Zymed) before the OPD reaction.
Analysis of transduction
To transduce cells, 3 ml of the virus-containing medium previously cleared of cellular debris was added to fresh 293T or SCP cells in six-well dishes (2 ϫ 10 5 SCP, 5 ϫ 10 5 293T seeded per well the previous day). Protamine sulfate (Sigma) and HEPES buffer was added to the wells at a final concentration of 4 g/ml and 10 mM, respectively, and the dishes were subjected to centrifugation ("spinoculation") at 3000 rpm for 2-3 h at 32-37°C. Spinoculation was used since the procedure brings more virions to the cells' membranes than would normally occur without centrifugation. After spinoculation, the dishes were placed back in the incubator for 30-60 min, then virus-containing medium was removed and fresh medium was added to the wells. Two to 3 days postspinoculation, a portion of the cells was removed from the plate by exposure to EDTA and analyzed for eGFP expression by flow cytometry using a FACScan (Becton Dickinson Biosciences).
Analysis of reverse-transcribed vector DNA
Sixteen to 24 h after spinoculation, a portion of the cells was lysed, then serial dilutions of the lysate were subjected to PCR to amplify a segment of the vector DNA synthesized near the end of reverse transcription. The primers used were VR (5Ј-GGAGAGCTCGAAGGAAA-GAGTC-3Ј), in the R region, and Vgag (5Ј-AGGAG-CAGCGTCCGTGGTCCC-3Ј), upstream of the gag start codon. For HIV-1-infected control cells, the analogous primers were M667 (5Ј-GGCTAACTAGGGAACCCACTG-3Ј) and M661 (5Ј-CCTGCGTCGAGAGAGCTCCTCTGG-3Ј). The reaction products were then subjected to agarose gel electrophoresis and ethidium bromide staining. The amount of vector DNA is inferred from the dilution in which the amplified band can no longer be detected and/or the relative intensities of the amplified bands, as detected by visual inspection. The efficiencies of the primer sets were determined using dilutions of the vector plasmids pHS-MPSVegfp and pVV2-MG. In addition, the cell-equivalents of the lysates were determined using ␤-globin primers LA1 and LA2 (Plavec et al., 1996) .
Analysis of integrated vector DNA levels
Genomic DNA was isolated from the cells 2 weeks after spinoculation using a commercial kit (Qiagen). Serial dilutions of the genomic DNA were subjected to PCR amplification using Visna primers VR and Vgag and HIV-1 primers M667 and M661 (see above). The reaction products were then subjected to agarose gel electrophoresis and ethidium bromide staining. The amount of vector DNA is inferred from the dilution in which the amplified band can no longer be detected and/or the relative intensities of the amplified bands, as detected by visual inspection. The cell-equivalents of the DNA preparations were determined using ␤-globin primers LA1 and LA2 (Plavec et al., 1996) .
